Liposomal cisplatin can overcome chemotherapy resistance of A2780 ovarian cancer cells by inducing the extrinsic apoptotic pathway.
@article{Stlting2014LiposomalCC,
title={Liposomal cisplatin can overcome chemotherapy resistance of A2780 ovarian cancer cells by inducing the extrinsic apoptotic pathway.},
author={Daniel Philipp St{\"o}lting and Martin Koch and Michael Wiese and Hans Dieter Royer and Gerd Bendas},
journal={International journal of clinical pharmacology and therapeutics},
year={2014},
volume={52 1},
pages={
78-81
}
}Cisplatin (CDDP) is a principal compo nent of standard ovarian cancer chemother apy. However, the frequent development of cellular resistance to CDDP severely restricts the clinical therapeutic success. The molecu lar mechanisms of resistance are manifold and not completely understood [1]. Previously, we reported that liposo mal CDDP overcomes CDDP resistance of A2780cis human ovarian cancer cells [2]. However, the superior cytotoxic activi ty of liposomal CDDP vs. the free drug in…
Figures from this paper
4 Citations
Cisplatin liposome and 6-amino nicotinamide combination to overcome drug resistance in ovarian cancer cells
- BiologyOncotarget
- 2018
The combination treatment of liposomal cisplatin and 6-amino nicotinamide showed promising cytotoxic activities in drug-resistant cells and a prolonged pharmacokinetics in rats, thus opening the way for a new therapeutic option against ovarian cancer.
Low molecular weight heparin tinzaparin antagonizes cisplatin resistance of ovarian cancer cells.
- BiologyBiochemical pharmacology
- 2015
Cytotoxicity of Nanoliposomal Cisplatin Coated with Synthesized Methoxypolyethylene Glycol Propionaldehyde in Human Ovarian Cancer Cell Line A2780CP
- Chemistry, Biology
- 2016
The findings show that the cytotoxicity of pegylated nanoliposomal cisplatin is higher than that of free cis Platin in human ovarian cancer cell line A2780CP and in vivo studies are, however, required to ascertain its therapeutic potentials.
Drug Delivery of Pegylated Nanoliposomal Cisplatin in Ovarian Cancer Cell Line A2780CP: in vitro Study
- Medicine
- 2017
It is confirmed that the £50m price tag of the A2780CP is likely to be higher than previously thought.
References
SHOWING 1-6 OF 6 REFERENCES
Overcoming chemotherapy resistance of ovarian cancer cells by liposomal cisplatin: molecular mechanisms unveiled by gene expression profiling.
- Biology, ChemistryBiochemical pharmacology
- 2013
Overcoming cisplatin resistance of ovarian cancer cells by targeted liposomes in vitro.
- Biology, ChemistryInternational journal of pharmaceutics
- 2010
Molecular mechanisms of cisplatin resistance
- Biology, ChemistryOncogene
- 2012
A systematic discussion of the mechanisms that account for the cisplatin-resistant phenotype of tumor cells are described and the development of chemosensitization strategies constitute a goal with important clinical implications.
Subcellular targets of cisplatin cytotoxicity: an integrated view.
- BiologyPharmacology & therapeutics
- 2012
Caspase control: protagonists of cancer cell apoptosis.
- BiologyExperimental oncology
- 2012
This review will discuss the current cellular landscape featuring the caspase family in tumor cells and their activation via pharmacologic intervention towards optimized anti-cancer therapeutic modalities.
Regulation of CD95/Fas signaling at the DISC
- BiologyCell Death and Differentiation
- 2012
This review is focused on the role in the CD95-mediated signaling of the death effector domain-containing proteins procaspase-8 and c-FLIP and discusses how dynamic cross-talk at the DISC regulates life/death decisions at CD95.
